...
首页> 外文期刊>Journal of the Formosan Medical Association =: Taiwan yi zhi >Effect of Recombinant Plasmid pEGFP-AFP-hTNF on Liver Cancer Cells (HepG2 Cells) in vitro when Delivered by PEG-PEI/Fe3O4 Nanomagnetic Fluid
【24h】

Effect of Recombinant Plasmid pEGFP-AFP-hTNF on Liver Cancer Cells (HepG2 Cells) in vitro when Delivered by PEG-PEI/Fe3O4 Nanomagnetic Fluid

机译:通过PEG-PEI / Fe3O4纳米磁性液体输送时重组质粒pEGFP-AFP-HTNF对肝癌细胞(HepG2细胞)的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Gene delivery into liver cancer cells has been a problem. This study aimed to understand the effect of using PEGI/Fe3O4 nanomagnetic fluid as a gene vector for liver cancer gene therapy. An AFP enhancer aids in the expression of tumor-specific foreign genes in AFP-producing cancer cells like HepG2 cells, and was utilized in the delivery method in this study. Methods: We constructed recombinant plasmid PEGFP-AFP-hTNFα, which was transfected into AFP positive HepG2 cells and AFP negative Hela cells by PEG-PEI/Fe3O4 nanomagnetic fluid. Fluorescence microscopy was used to evaluate the transfection rate of the hTNFα gene in the HepG2 cells 12 hours after transfection. Reverse transcription polymerase chain reaction (RT-PCR) and western blot were used to detect expression of hTNFα gene in the HepG2 cells 48 hours after transfection. Methyl thiazolyl tetrazolium (MTT) assay was used to evaluate the inhibitory effect of hTNFα on the proliferation of HepG2 cells. Flow cytometry was used to analyze the apoptosis of HepG2 cells. Results: Plasmid PEGFP-AFP-hTNFα delivered by PEG-PEI/Fe3O4 nanomagnetic fluid was successfully transfected into HepG2 cells and expressed in the HepG2 cells. The transfection efficacy of hTNFα gene delivered by PEG-PEI/Fe3O4 nanomagnetic fluid was superior to that of hTNFα gene delivered by lipofectamine in HepG2 cells. RT-PCR and western blot demonstrated that hTNFα gene was expressed in HepG2 cells that were transfected with complexes of nanomagnetic fluid/PEGFP-AFP-hTNFα. MTT and flow cytometry showed that the hTNFα gene markedly exerted a cell killing effect. Conclusion: PEG-PEI/Fe3O4 nanomagnetic fluid successfully transfected PEGFP-AFP-hTNFα into HepG2 cells and induced expression of hTNFα gene in the HepG2 cells, thus showing promise as a gene vector for liver cancer gene therapy. Furthermore, an AFP enhancer can specifically increase the expression of target genes in cells positive for AFP.
机译:基因递送到肝癌细胞中是一个问题。本研究旨在了解使用PEGI / Fe3O4纳米磁性流体作为肝癌基因治疗的基因载体的影响。 AFP增强剂有助于表达肿瘤特异性外源基因,如HepG2细胞等AFP的癌细胞,并在本研究中的递送方法中使用。方法:通过PEG-PEI / Fe 3 O 4纳米磁性液体构建重组质粒pEGFP-AFP-HTNFα,其通过PEG-PEI / Fe 3 O 4纳米磁性转移到AFP阳性HepG2细胞和AFP阴性HeLa细胞中。荧光显微镜用于在转染后12小时评价HEPG2细胞中HTNFα基因的转染率。逆转录聚合酶链反应(RT-PCR)和Western印迹用于在转染后48小时检测HEPG2细胞中HTNFα基因的表达。甲基噻唑基四唑(MTT)测定用于评估HTNFα对HepG2细胞增殖的抑制作用。流式细胞术用于分析HepG2细胞的凋亡。结果:通过PEG-PEI / Fe3O4纳米磁性流体递送的质粒PEGFP-AFP-HTNFα成功转染到HEPG2细胞中并在HepG2细胞中表达。 PEG-PEI / Fe 3 O4纳米磁性流体递送的HTNFα基因的转染功效优于HepG2细胞脂质溶解胺递送的HTNFα基因的转染效果。 RT-PCR和Western印迹表明HTNFα基因在用纳米磁性/ PEGFP-AFP-HTNFα的复合物转染的HepG2细胞中表达。 MTT和流式细胞术显示HTNFα基因明显施加细胞杀伤效果。结论:PEG-PEI / Fe3O4纳米磁性成功转染PEGFP-AFP-HTNFα进入HEPG2细胞,并诱导HEPG2细胞中HTNFα基因的表达,从而显示为肝癌基因治疗的基因载体。此外,AFP增强剂可以明确增加AFP阳性细胞中靶基因的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号